CREBBP/EP300 acetyltransferase inhibition targets lineage specific enhancers to inhibit the proliferation of ER+ breast cancer cells [RNA-Seq]

MCF7, T47D, or ZR751 cells were treated with a CREBBP/EP300 acetyltransferase inhibitor CPI-1612 and/or Fulvestrant and expression changes were measured via RNA-seq MCF7, T47D, or ZR751 cells were treated with DMSO, CPI-1612 (5 nM, 50 nM) or Fulvestrant (100 nM), or combinations of CPI-1612 + Fulvestrant. Whole RNA was extracted and used for library construction and RNA-sequencing.